Half-Year Report Reveals Strong Cash Position and Clinical Momentum, Bolstered by Dr. Reddy's Upfront Payment

summarizeSummary

Immutep's half-year report shows a pro-forma cash balance of A$129.3 million, significantly strengthened by a A$29.9 million upfront payment from Dr. Reddy's and a A$30 million vendor payment deferral, alongside continued positive clinical trial progress.

check_boxKey Events

• Significant Cash Injection from Dr. Reddy's Collaboration

  The company reported a pro-forma cash and short-term investments balance of A$129.3 million as of December 31, 2025, following the receipt of a A$29.9 million (USD 20 million) upfront payment from Dr. Reddy's in January 2026. This payment was previously announced on January 30, 2026, and is now reflected in the financial report.

• Vendor Payment Deferral Boosts Liquidity

  A long-term vendor agreed to defer approximately A$30 million in payments for future Biologics License Application (BLA) readiness services by up to 30 months, further strengthening the company's cash runway.

• Increased R&D Expenses Drive Higher Net Loss

  The net loss for the half-year ended December 31, 2025, increased to A$44.86 million, primarily due to a A$21.3 million increase in R&D and intellectual property expenses as clinical trial activities for eftilagimod alfa and IMP761 advanced.

• Positive Clinical Trial Progress Across Multiple Programs

  The report detailed ongoing progress in the pivotal TACTI-004 Phase III trial (50% patient enrollment achieved by early February 2026, futility analysis on track for Q1 CY2026), positive FDA feedback for TACTI-003 (HNSCC) and AIPAC-003 (MBC), and promising data from EFTISARC-NEO (STS) and INSIGHT-003 (NSCLC).

auto_awesomeAnalysis

Immutep's half-year financial report highlights a significantly strengthened balance sheet, primarily driven by the A$29.9 million upfront payment from the Dr. Reddy's collaboration, which was received in January 2026. This payment, representing approximately 7.3% of the company's market capitalization, substantially boosts the pro-forma cash balance to A$129.3 million and extends the company's operational runway. Further enhancing liquidity, a long-term vendor agreed to defer A$30 million in payments for future services. While the company reported an increased net loss due to higher R&D expenses, this is a typical and expected outcome for a clinical-stage biotech advancing multiple programs. The report also provides comprehensive updates on positive clinical trial progress across several indications, including favorable FDA feedback for TACTI-003 and AIPAC-003, and promising data from EFTISARC-NEO and INSIGHT-003. This combination of robust financing and continued clinical advancement positions Immutep favorably for upcoming milestones.